Q1 2025 Scholar Rock Holding Corp Earnings Call Transcript
Key Points
- Scholar Rock Holding Corp (SRRK) reported a strong start to 2025 with significant progress in bringing apitegromab to patients with SMA.
- The Phase III SAPPHIRE trial showed statistically significant and clinically meaningful improvement in motor function for SMA patients.
- The FDA granted priority review for the BLA of apitegromab, with a PDUFA date set for September 22, indicating potential for significant impact.
- Scholar Rock is preparing for a US commercial launch of apitegromab in Q3, with plans for global expansion in Europe, Asia Pacific, and Latin America.
- The company is exploring the potential of apitegromab in other neuromuscular disorders and advancing SRK-439, a new anti-myostatin antibody, to the clinic.
- There are concerns about the state of the FDA, although Scholar Rock reports constructive interactions regarding apitegromab's review.
- The company faces challenges in ensuring payer coverage for combination therapies targeting both SMN and muscle in SMA patients.
- The EMBRAZE study in the cardiometabolic space is exploratory, with uncertainties about the role of apitegromab in obesity treatment.
- Launch dynamics for apitegromab may face headwinds due to existing SMA treatments, despite the unmet need for muscle-targeted therapies.
- The potential impact of the President's executive order on drug pricing introduces uncertainty in pricing strategies for apitegromab.
Ladies and gentlemen, thank you for standing by, and welcome to Scholar Rock's first-quarter financial results and business update call. (Operator Instructions)
Please be advised that today's conference is being recorded. I would like now to turn the conference over to Scholar Rock.
Good morning. I'm Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock. With me today are David Hallal, Chief Executive Officer; Akshay Vaishnaw, President of R&D; Keith Woods, Chief Operating Officer; and Vikas Sinha, Chief Financial Officer.
For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page on our website. During today's call, as outlined on slide 2, David will provide introductory remarks and provide a general business update, Akshay will review our clinical and regulatory progress, Keith will provide an update on our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
